# Biologic Overview 

Hannah Lomzenski

---

## Background

- "-cept" refers to fusion of a receptor to the Fc part of human
    immunoglobulin G1 (IgG1)

- "-mab" indicates a monoclonal antibody (mAb)

- "-ximab" indicates a chimeric mAb

- "-zumab" indicates a humanized mAb

- "-umab" indicates a fully human mAb

- “-tinib” indicates a tyrosine kinase inhibitor (small molecule
    inhibitors, not true biologics)

# Selected biologics

# Kinase inhibition

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 22%" />
<col style="width: 22%" />
<col style="width: 35%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Tofacitinib</p>
<p>(Xeljanz)</p></td>
<td>JAK-1 and JAK-3 inhibitor</td>
<td>RA, UC, JIA, psoriatic arthritis</td>
<td>nasopharyngitis, skin rash, GI sx, GU sx; &lt;1% lymphoma</td>
</tr>
<tr class="even">
<td><p>Baracitinib</p>
<p>(Olumiant)</p></td>
<td>JAK-1 and JAK-2 inhibitor</td>
<td>RA; off-label: COVID-19</td>
<td>URI, nausea, ⇑AST/ALT; &lt;1% lymphoma</td>
</tr>
<tr class="odd">
<td><p>Upadacitinib</p>
<p>(Rinvoq)</p></td>
<td>non-specific JAK inhibitor</td>
<td>RA</td>
<td>URI, nausea, neutropenia, ⇑AST, ⇑CPK</td>
</tr>
</tbody>
</table>

# IL-1 inhibition

<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 16%" />
<col style="width: 35%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Anakinra</p>
<p>(Kineret)</p></td>
<td>IL-1 receptor antagonist</td>
<td>IL-1 receptor antagonist deficiency, gout flares, FMF, HLH</td>
<td>HA, vomiting, infections, nasopharyngitis, Ab development; in RA:
eosinophilia, decreased WBC</td>
</tr>
<tr class="even">
<td><p>Canakinumab</p>
<p>(Ilaris)</p></td>
<td>mAb against IL-1β</td>
<td>Cryoporin-associated periodic syndromes (CAPS), FMF,
hyperimmunoglobin D syndrome, TRAPS; off-label: gout flare</td>
<td>Weight gain, GI sx, HA, vertigo, serious infections</td>
</tr>
</tbody>
</table>

# IL-17 inhibition

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 25%" />
<col style="width: 16%" />
<col style="width: 38%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Secukinumab</p>
<p>(Cosentyx)</p></td>
<td>human IgG1 mAb against IL-17A</td>
<td>AS, psoriasis</td>
<td>nasopharyngitis, GI, IBD (&lt;1%)</td>
</tr>
<tr class="even">
<td><p>Ixekizumab</p>
<p>(Taltz)</p></td>
<td>human IgG4 mAb against IL-17A</td>
<td>AS, psoriasis</td>
<td>neutropenia, Ab development, URI, Crohn’s (&lt;1%)</td>
</tr>
</tbody>
</table>

# IL-6 inhibition

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 26%" />
<col style="width: 24%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Tocilizumab</p>
<p>(Actemra)</p></td>
<td>IL-6 receptor antagonist</td>
<td>cytokine release syndrome, giant cell arteritis, RA, JIA</td>
<td>⇑ serum cholesterol, ⇑ AST/ALT, infusion rxn, HSV infection
(&lt;2%)</td>
</tr>
<tr class="even">
<td><p>Sarilumab</p>
<p>(Kevzara)</p></td>
<td>IL-6 receptor antagonist (soluble + membrane-bound)</td>
<td>RA</td>
<td>⇑ AST/ALT, HSV infection (&lt;2%)</td>
</tr>
</tbody>
</table>

# IL-12/23 inhibition

<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 23%" />
<col style="width: 28%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Ustekinumab</p>
<p>(Stelara)</p></td>
<td>mAb against IL-12 + IL-23</td>
<td>IBD, psoriasis</td>
<td>nasopharyngitis, Ab development, acne vulgaris, GI sx, GU sx</td>
</tr>
<tr class="even">
<td><p>Guselkumab</p>
<p>(Tremfya)</p></td>
<td>human IgG1 mAb against IL-23</td>
<td>psoriasis</td>
<td>URI, tinea, GI sx</td>
</tr>
</tbody>
</table>

# Costimulation blockade

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 38%" />
<col style="width: 14%" />
<col style="width: 27%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Abatacep</p>
<p>(Orencia)</p></td>
<td>inhibits T-cell activation by binding CD80 and CD86 on APCs, thus
blocking the required CD28 ixn between APCs and T cells.</td>
<td>RA, psoriasis, JIA</td>
<td>nausea, UTI, HA, URI, Ab development</td>
</tr>
</tbody>
</table>

# B-cell depletion and inhibition

<table style="width:100%;">
<colgroup>
<col style="width: 18%" />
<col style="width: 25%" />
<col style="width: 28%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Rituximab</p>
<p>(Rituxan)</p></td>
<td>mAb against the CD20 antigen on surface of B-lymphocytes</td>
<td>CLL, Non-Hodgkin lymphomas, GPA, microscopic polyangiitis, pemphigus
vulgaris, RA; many off-label uses (GvHD, lupus nephritis, MG,
neuromyelitis optica)</td>
<td>HTN, peripheral edema, night sweats, fever, weight gain, angioedema,
arthralgias, ⇑ ALT, hypophosphatemia, hematologic abnormalities</td>
</tr>
<tr class="even">
<td><p>Belimumab</p>
<p>(Benlysta)</p></td>
<td>IgG1-lambda mAb that prevents survival of B-lymphocytes by blocking
the binding of soluble human B lymphocyte stimulator protein (BLyS) to
receptors on B lymphocytes</td>
<td>lupus nephritis, SLE</td>
<td>GI symptoms, hypersensitivity reaction, infections, psychiatric
disturbances</td>
</tr>
</tbody>
</table>

# TNF-inhibition

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 28%" />
<col style="width: 25%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Adalilumab</p>
<p>(Humira)</p></td>
<td>mAb against TNFα</td>
<td>RA, IBD, AS, psoriasis, uveitis, hidradenitis suppurativa</td>
<td>skin rash, HA, URI, ⇑ CPK, +ANA titer (12%), Ab development
(3-26%)</td>
</tr>
<tr class="even">
<td><p>Certolizumab</p>
<p>(Cimzia)</p></td>
<td>humanized mAb Fab fragment against TNFα</td>
<td>RA, Crohn’s, AS, psoriasis; \*approved for use during pregnancy</td>
<td>skin rash, nausea, URI</td>
</tr>
<tr class="odd">
<td><p>Etanercept</p>
<p>(Enbrel)</p></td>
<td>tumor necrosis factor receptor linked to Fc portion of IgG1; binds
TNF</td>
<td>RA, AS, psoriasis, JIA</td>
<td><p>skin rash, diarrhea,</p>
<p>+ANA titer (11%)</p></td>
</tr>
<tr class="even">
<td><p>Infliximab</p>
<p>(Remicade)</p></td>
<td>chimeric mAb against TNFα</td>
<td>RA, IBD, AS, psoriasis</td>
<td>abd pain, URI sx, anemia, ⇑ ALT, Ab development (10-50%)</td>
</tr>
<tr class="odd">
<td><p>Golimumab</p>
<p>(Simponi)</p></td>
<td>mAb against TNFα</td>
<td>RA, UC, AS, psoriasis, JIA</td>
<td>URI, Ab development (16-38%), +ANA titer (4-17%)</td>
</tr>
</tbody>
</table>
